Author

L. Gallucci

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:host-pathogen & immune response· 1 Research Focus:perturbation response prediction· 1

Frequent Co-Authors

I. L. Shytaj· 2 shared A. D. Davidson· 1 shared A. Savarino· 1 shared A. T. Ayoub· 1 shared B. Lucic· 1 shared C. J. Neufeldt· 1 shared J. Bazire· 1 shared L. Zimmermann· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

I. L. Shytaj

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Broad-spectrum antiviral activity of clinically approved CYP3A inhibitors against pathogenic human coronaviruses in vitro

L. Gallucci, J. Bazire, A. D. Davidson, I. L. Shytaj

This study shows that cobicistat and ritonavir have antiviral activity against multiple SARS-CoV-2 variants and other human coronaviruses, with cobicistat being more potent.

bioRxiv · Aug 23, 2023 · PreprintMicrobiology

The FDA-approved drug cobicistat synergizes with remdesivir to inhibit SARS-CoV-2 replication

I. L. Shytaj, M. Fares, B. Lucic, L. Gallucci, M. M. Tolba, L. Zimmermann, A. T. Ayoub, M. Cortese, C. J. Neufeldt, V. Laketa, P. Chlanda, O. T. Fackler, S. Boulant, R. Bartenschlager, M. Stanifer, , M. Lusic

This study shows that cobicistat synergizes with remdesivir to inhibit SARS-CoV-2 replication in cell lines and organoids, reducing viral replication to levels comparable to uninfected cells.

bioRxiv · Mar 9, 2021Microbiology